FDA Issues Complete Response Letter for Etripamil for PSVT

Stock Information for Milestone Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.